Review





Similar Products

95
ACROBiosystems biotinylated human vegf165 protein
Biotinylated Human Vegf165 Protein, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/biotinylated/Biotinylated+Human+VEGF165+Protein%2C+His%2CAvitag/pmc13752511-52-0-13
Average 95 stars, based on 1 article reviews
biotinylated human vegf165 protein - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

90
R&D Systems eph receptor family anti epha4 baf641
Eph Receptor Family Anti Epha4 Baf641, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/biotinylated/Mouse+EphA4+Biotinylated+Antibody/pm43015303-306-56-61
Average 90 stars, based on 1 article reviews
eph receptor family anti epha4 baf641 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

95
ACROBiosystems biotinylated human cd19 20 291 protein
Biotinylated Human Cd19 20 291 Protein, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/biotinylated/Biotinylated+Human+CD19+(20-291)+Protein%2C+His%2CAvitag+(SPR+verified)+DMF+Filed/pm42987830-188-280-285
Average 95 stars, based on 1 article reviews
biotinylated human cd19 20 291 protein - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

96
Jackson Immuno biotinylated donkey anti goat igg
Biotinylated Donkey Anti Goat Igg, supplied by Jackson Immuno, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/biotinylated/Donkey+Anti-Goat+IgG/pm42985923-79-1-6
Average 96 stars, based on 1 article reviews
biotinylated donkey anti goat igg - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

95
ACROBiosystems biotinylated human cd19
Biotinylated Human Cd19, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/biotinylated/Biotinylated+Human+CD19+(20-291)+Protein%2C+His%2CAvitag+(SPR+verified)+DMF+Filed/bio_rxiv__64898__2026__11__02__763574-158-26-29
Average 95 stars, based on 1 article reviews
biotinylated human cd19 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

94
MedChemExpress biotinylated pacap 38
This workflow outlines the design of <t>PACAP-38</t> binders in this study. The three-dimensional structure of PACAP-38 (magenta) was extracted from the cryo-EM structure of the PAC1/PACAP-38 complex (PDB ID: 6M1I) . In this PACAP-38 structure, the C-terminal residues (residues 28–38) are disordered. The three-dimensional structures of the binders designed using Bindcraft are shown in green, along with the length distribution of the 100 binders (top centre). The candidate mutant residues identified by alanine scanning of ICLIST-2, which was discovered through ELISA screening, are shown in red (bottom right).
Biotinylated Pacap 38, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/biotinylated/PACAP+(1-38)%2C+amide%2C+Biotin-labeled/bio_rxiv__64898__2026__10__30__763049-228-14-17
Average 94 stars, based on 1 article reviews
biotinylated pacap 38 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
R&D Systems biotinylated dr5 antibody
a, Representative flow cytometry analysis and quantification of total (surface and intracellular) TRAIL expression in ILC1s and NK cells in the lungs and livers of C57BL/6 mice with or without E0771 cancer cell challenge for 24 h. TRAIL mean fluorescence intensity (MFI) is shown as mean ± s.e.m. b , Representative bioluminescence images and radiance quantification of lung and liver colonization of parental (n = 6) and <t>DR5-deficient</t> ( Tnfrsf10b −/− ; n = 11) E0771 cancer cells. One representative image shown. Data are representative of at least three independent experiments. Radiance quantification is shown as mean ± s.e.m. c , Identification of AP-2α (encoded by Tfap2a ) as a critical regulator of DR5 expression in E0771 cancer cells using a CRISPR-Cas9 screen. Volcano plot showing Log 2 (fold change, FC) versus - Log 2 ( P value) of genes identified by Illumina sequencing analysis. Each point represents an individual gene. Log₂ fold change (Log₂ FC) represents the enrichment or depletion of individual sgRNAs in the DR5-low cell population relative to their abundance in the unsorted library. Positive values denote sgRNAs enriched in DR5-low cells. d , Representative flow cytometry analysis and quantification of DR5 expression in parental and Tfap2a −/− E0771 cancer cells. DR5 MFI is normalized to background signals from Tnfrsf10b −/− E0771 cancer cells. e , Representative bioluminescence images and radiance quantification of lung and liver colonization of parental (n = 6) and AP-2α-deficient ( Tfap2a −/− ; n = 6) E0771 cancer cells. One representative image shown. Data are representative of at least three independent experiments. Radiance quantification is shown as mean ± s.e.m. f , Chromatin immunoprecipitation followed by qPCR (CHIP-qPCR) analysis of AP-2α binding to the Tnfrsf10b gene locus in parental E0771 cancer cells and in cells with knockout of the predicted AP-2α binding sites (BS KO) at the Tnfrsf10b gene locus. Enrichment of DNA immunoprecipitated with anti-AP-2α relative to control IgG was quantified over input DNA. g , Representative flow cytometry analysis and quantification of DR5 expression in parental and BS KO E0771 cancer cells. DR5 MFI is normalized to background signal from Tnfrsf10b −/− E0771 cancer cells. h , Representative bioluminescence images and radiance quantification of lung and liver colonization of parental (n = 5) and BS KO (n = 5) E0771 cancer cells. One representative image shown. Data are representative of at least three independent experiments. Radiance quantification is shown as mean ± s.e.m. i , TNFRSF10B gene copy number in breast cancer patients with or without liver or lung metastases. Violin plots show log 2 -transformed fold changes in copy number, with each dot representing an individual patient sample and the horizontal line indicating the median. j , Association between TNFRSF10B gene copy number and mRNA expression. Expression levels of TNFRSF10B (z-score) are compared between samples with diploid or heterozygous deletion (het loss) of TNFRSF10B . k , Breast cancer patient survival stratified by TNFRSF10B copy number status (diploid versus het loss). P values were calculated using Welch’s t -test ( a , b , d - h ), Wilcoxon rank-sum test ( i , j ), and the log-rank (Mantel-Cox) test ( k ). ns: not significant ( P > 0.05).
Biotinylated Dr5 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/biotinylated/Mouse+TRAIL+R2%2FTNFRSF10B+Biotinylated+Antibody/bio_rxiv__64898__2026__10__26__759951-215-11-14
Average 94 stars, based on 1 article reviews
biotinylated dr5 antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

95
DiaSorin Biotechnology avitag biotinylated sars cov 2 rbd conjugated magplex avidin beads
a, Representative flow cytometry analysis and quantification of total (surface and intracellular) TRAIL expression in ILC1s and NK cells in the lungs and livers of C57BL/6 mice with or without E0771 cancer cell challenge for 24 h. TRAIL mean fluorescence intensity (MFI) is shown as mean ± s.e.m. b , Representative bioluminescence images and radiance quantification of lung and liver colonization of parental (n = 6) and <t>DR5-deficient</t> ( Tnfrsf10b −/− ; n = 11) E0771 cancer cells. One representative image shown. Data are representative of at least three independent experiments. Radiance quantification is shown as mean ± s.e.m. c , Identification of AP-2α (encoded by Tfap2a ) as a critical regulator of DR5 expression in E0771 cancer cells using a CRISPR-Cas9 screen. Volcano plot showing Log 2 (fold change, FC) versus - Log 2 ( P value) of genes identified by Illumina sequencing analysis. Each point represents an individual gene. Log₂ fold change (Log₂ FC) represents the enrichment or depletion of individual sgRNAs in the DR5-low cell population relative to their abundance in the unsorted library. Positive values denote sgRNAs enriched in DR5-low cells. d , Representative flow cytometry analysis and quantification of DR5 expression in parental and Tfap2a −/− E0771 cancer cells. DR5 MFI is normalized to background signals from Tnfrsf10b −/− E0771 cancer cells. e , Representative bioluminescence images and radiance quantification of lung and liver colonization of parental (n = 6) and AP-2α-deficient ( Tfap2a −/− ; n = 6) E0771 cancer cells. One representative image shown. Data are representative of at least three independent experiments. Radiance quantification is shown as mean ± s.e.m. f , Chromatin immunoprecipitation followed by qPCR (CHIP-qPCR) analysis of AP-2α binding to the Tnfrsf10b gene locus in parental E0771 cancer cells and in cells with knockout of the predicted AP-2α binding sites (BS KO) at the Tnfrsf10b gene locus. Enrichment of DNA immunoprecipitated with anti-AP-2α relative to control IgG was quantified over input DNA. g , Representative flow cytometry analysis and quantification of DR5 expression in parental and BS KO E0771 cancer cells. DR5 MFI is normalized to background signal from Tnfrsf10b −/− E0771 cancer cells. h , Representative bioluminescence images and radiance quantification of lung and liver colonization of parental (n = 5) and BS KO (n = 5) E0771 cancer cells. One representative image shown. Data are representative of at least three independent experiments. Radiance quantification is shown as mean ± s.e.m. i , TNFRSF10B gene copy number in breast cancer patients with or without liver or lung metastases. Violin plots show log 2 -transformed fold changes in copy number, with each dot representing an individual patient sample and the horizontal line indicating the median. j , Association between TNFRSF10B gene copy number and mRNA expression. Expression levels of TNFRSF10B (z-score) are compared between samples with diploid or heterozygous deletion (het loss) of TNFRSF10B . k , Breast cancer patient survival stratified by TNFRSF10B copy number status (diploid versus het loss). P values were calculated using Welch’s t -test ( a , b , d - h ), Wilcoxon rank-sum test ( i , j ), and the log-rank (Mantel-Cox) test ( k ). ns: not significant ( P > 0.05).
Avitag Biotinylated Sars Cov 2 Rbd Conjugated Magplex Avidin Beads, supplied by DiaSorin Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/biotinylated/MagPlex-Avidin+microspheres/pm42962933-246-14-19
Average 95 stars, based on 1 article reviews
avitag biotinylated sars cov 2 rbd conjugated magplex avidin beads - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

91
R&D Systems alcam cd166 biotin
a, Representative flow cytometry analysis and quantification of total (surface and intracellular) TRAIL expression in ILC1s and NK cells in the lungs and livers of C57BL/6 mice with or without E0771 cancer cell challenge for 24 h. TRAIL mean fluorescence intensity (MFI) is shown as mean ± s.e.m. b , Representative bioluminescence images and radiance quantification of lung and liver colonization of parental (n = 6) and <t>DR5-deficient</t> ( Tnfrsf10b −/− ; n = 11) E0771 cancer cells. One representative image shown. Data are representative of at least three independent experiments. Radiance quantification is shown as mean ± s.e.m. c , Identification of AP-2α (encoded by Tfap2a ) as a critical regulator of DR5 expression in E0771 cancer cells using a CRISPR-Cas9 screen. Volcano plot showing Log 2 (fold change, FC) versus - Log 2 ( P value) of genes identified by Illumina sequencing analysis. Each point represents an individual gene. Log₂ fold change (Log₂ FC) represents the enrichment or depletion of individual sgRNAs in the DR5-low cell population relative to their abundance in the unsorted library. Positive values denote sgRNAs enriched in DR5-low cells. d , Representative flow cytometry analysis and quantification of DR5 expression in parental and Tfap2a −/− E0771 cancer cells. DR5 MFI is normalized to background signals from Tnfrsf10b −/− E0771 cancer cells. e , Representative bioluminescence images and radiance quantification of lung and liver colonization of parental (n = 6) and AP-2α-deficient ( Tfap2a −/− ; n = 6) E0771 cancer cells. One representative image shown. Data are representative of at least three independent experiments. Radiance quantification is shown as mean ± s.e.m. f , Chromatin immunoprecipitation followed by qPCR (CHIP-qPCR) analysis of AP-2α binding to the Tnfrsf10b gene locus in parental E0771 cancer cells and in cells with knockout of the predicted AP-2α binding sites (BS KO) at the Tnfrsf10b gene locus. Enrichment of DNA immunoprecipitated with anti-AP-2α relative to control IgG was quantified over input DNA. g , Representative flow cytometry analysis and quantification of DR5 expression in parental and BS KO E0771 cancer cells. DR5 MFI is normalized to background signal from Tnfrsf10b −/− E0771 cancer cells. h , Representative bioluminescence images and radiance quantification of lung and liver colonization of parental (n = 5) and BS KO (n = 5) E0771 cancer cells. One representative image shown. Data are representative of at least three independent experiments. Radiance quantification is shown as mean ± s.e.m. i , TNFRSF10B gene copy number in breast cancer patients with or without liver or lung metastases. Violin plots show log 2 -transformed fold changes in copy number, with each dot representing an individual patient sample and the horizontal line indicating the median. j , Association between TNFRSF10B gene copy number and mRNA expression. Expression levels of TNFRSF10B (z-score) are compared between samples with diploid or heterozygous deletion (het loss) of TNFRSF10B . k , Breast cancer patient survival stratified by TNFRSF10B copy number status (diploid versus het loss). P values were calculated using Welch’s t -test ( a , b , d - h ), Wilcoxon rank-sum test ( i , j ), and the log-rank (Mantel-Cox) test ( k ). ns: not significant ( P > 0.05).
Alcam Cd166 Biotin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/biotinylated/Mouse+ALCAM%2FCD166+Biotinylated+Antibody/pm42965868-216-81-83
Average 91 stars, based on 1 article reviews
alcam cd166 biotin - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

95
R&D Systems leptin r biotin
a, Representative flow cytometry analysis and quantification of total (surface and intracellular) TRAIL expression in ILC1s and NK cells in the lungs and livers of C57BL/6 mice with or without E0771 cancer cell challenge for 24 h. TRAIL mean fluorescence intensity (MFI) is shown as mean ± s.e.m. b , Representative bioluminescence images and radiance quantification of lung and liver colonization of parental (n = 6) and <t>DR5-deficient</t> ( Tnfrsf10b −/− ; n = 11) E0771 cancer cells. One representative image shown. Data are representative of at least three independent experiments. Radiance quantification is shown as mean ± s.e.m. c , Identification of AP-2α (encoded by Tfap2a ) as a critical regulator of DR5 expression in E0771 cancer cells using a CRISPR-Cas9 screen. Volcano plot showing Log 2 (fold change, FC) versus - Log 2 ( P value) of genes identified by Illumina sequencing analysis. Each point represents an individual gene. Log₂ fold change (Log₂ FC) represents the enrichment or depletion of individual sgRNAs in the DR5-low cell population relative to their abundance in the unsorted library. Positive values denote sgRNAs enriched in DR5-low cells. d , Representative flow cytometry analysis and quantification of DR5 expression in parental and Tfap2a −/− E0771 cancer cells. DR5 MFI is normalized to background signals from Tnfrsf10b −/− E0771 cancer cells. e , Representative bioluminescence images and radiance quantification of lung and liver colonization of parental (n = 6) and AP-2α-deficient ( Tfap2a −/− ; n = 6) E0771 cancer cells. One representative image shown. Data are representative of at least three independent experiments. Radiance quantification is shown as mean ± s.e.m. f , Chromatin immunoprecipitation followed by qPCR (CHIP-qPCR) analysis of AP-2α binding to the Tnfrsf10b gene locus in parental E0771 cancer cells and in cells with knockout of the predicted AP-2α binding sites (BS KO) at the Tnfrsf10b gene locus. Enrichment of DNA immunoprecipitated with anti-AP-2α relative to control IgG was quantified over input DNA. g , Representative flow cytometry analysis and quantification of DR5 expression in parental and BS KO E0771 cancer cells. DR5 MFI is normalized to background signal from Tnfrsf10b −/− E0771 cancer cells. h , Representative bioluminescence images and radiance quantification of lung and liver colonization of parental (n = 5) and BS KO (n = 5) E0771 cancer cells. One representative image shown. Data are representative of at least three independent experiments. Radiance quantification is shown as mean ± s.e.m. i , TNFRSF10B gene copy number in breast cancer patients with or without liver or lung metastases. Violin plots show log 2 -transformed fold changes in copy number, with each dot representing an individual patient sample and the horizontal line indicating the median. j , Association between TNFRSF10B gene copy number and mRNA expression. Expression levels of TNFRSF10B (z-score) are compared between samples with diploid or heterozygous deletion (het loss) of TNFRSF10B . k , Breast cancer patient survival stratified by TNFRSF10B copy number status (diploid versus het loss). P values were calculated using Welch’s t -test ( a , b , d - h ), Wilcoxon rank-sum test ( i , j ), and the log-rank (Mantel-Cox) test ( k ). ns: not significant ( P > 0.05).
Leptin R Biotin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/biotinylated/Mouse+Leptin+R+Biotinylated+Antibody/pm42965868-216-64-67
Average 95 stars, based on 1 article reviews
leptin r biotin - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

Image Search Results


This workflow outlines the design of PACAP-38 binders in this study. The three-dimensional structure of PACAP-38 (magenta) was extracted from the cryo-EM structure of the PAC1/PACAP-38 complex (PDB ID: 6M1I) . In this PACAP-38 structure, the C-terminal residues (residues 28–38) are disordered. The three-dimensional structures of the binders designed using Bindcraft are shown in green, along with the length distribution of the 100 binders (top centre). The candidate mutant residues identified by alanine scanning of ICLIST-2, which was discovered through ELISA screening, are shown in red (bottom right).

Journal: bioRxiv

Article Title: De novo design of mini-proteins as specific binders to PACAP-38, a key mediator of migraine

doi: 10.64898/2026.10.30.763049

Figure Lengend Snippet: This workflow outlines the design of PACAP-38 binders in this study. The three-dimensional structure of PACAP-38 (magenta) was extracted from the cryo-EM structure of the PAC1/PACAP-38 complex (PDB ID: 6M1I) . In this PACAP-38 structure, the C-terminal residues (residues 28–38) are disordered. The three-dimensional structures of the binders designed using Bindcraft are shown in green, along with the length distribution of the 100 binders (top centre). The candidate mutant residues identified by alanine scanning of ICLIST-2, which was discovered through ELISA screening, are shown in red (bottom right).

Article Snippet: The binding capacity of each binder was analyzed by ELISA, in triple repeats, using biotinylated PACAP-38 (HY-P2609F, MedChemExpress) as the antigen.

Techniques: Cryo-Electron Microscopy, Mutagenesis, Enzyme-linked Immunosorbent Assay, Screening, In Silico

A Binding responses of the top 20 Bindcraft-designed binders for PACAP-38 in ELISA. The control shows a sample without PACAP-38. B Concentration-dependent ELISA binding responses of ICLIST-1 (ID 7), ICLIST-2 (ID 17) and ICLIST-3 (ID 18), for a fixed concentration of PACAP-38 (0.1 μg/mL). Fitting was performed using GraphPad Prism 10.6.1. The figures show the relative response, with the binding response at the highest concentration of each binder set to 1. C The predicted structure of the complex between ICLIST-2 (green) and PACAP-38 (residue numbers 1–27, pink). D Binding responses of N-terminal and C-terminal truncations of ICLIST-2 binding to PACAP-38. The control represents wells without added PACAP-38. E E max of tandem ICLIST-2, with ICLIST-2 set to 100%. The experiment was performed three times and the mean ± S.D. is shown.

Journal: bioRxiv

Article Title: De novo design of mini-proteins as specific binders to PACAP-38, a key mediator of migraine

doi: 10.64898/2026.10.30.763049

Figure Lengend Snippet: A Binding responses of the top 20 Bindcraft-designed binders for PACAP-38 in ELISA. The control shows a sample without PACAP-38. B Concentration-dependent ELISA binding responses of ICLIST-1 (ID 7), ICLIST-2 (ID 17) and ICLIST-3 (ID 18), for a fixed concentration of PACAP-38 (0.1 μg/mL). Fitting was performed using GraphPad Prism 10.6.1. The figures show the relative response, with the binding response at the highest concentration of each binder set to 1. C The predicted structure of the complex between ICLIST-2 (green) and PACAP-38 (residue numbers 1–27, pink). D Binding responses of N-terminal and C-terminal truncations of ICLIST-2 binding to PACAP-38. The control represents wells without added PACAP-38. E E max of tandem ICLIST-2, with ICLIST-2 set to 100%. The experiment was performed three times and the mean ± S.D. is shown.

Article Snippet: The binding capacity of each binder was analyzed by ELISA, in triple repeats, using biotinylated PACAP-38 (HY-P2609F, MedChemExpress) as the antigen.

Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Control, Concentration Assay, Residue

A Predicted ΔΔG (kcal/mol) values upon, using FoldX , , and binding response measured by ELISA, for the nine alanine substitutions located in the vicinity of PACAP-38 (left axis). Binding response measured by ELISA (right axis). B Structural mapping (green) of the nine residues located in the vicinity of PACAP-38, which are defined as the core region. The side chains of these nine residues are shown as a ball-and-stick model in green, while ICLIST-2 is shown as an orange ribbon model and PACAP-38 as a grey ribbon model. C Alanine scanning of ICLIST-2. The binding of each mutant to PACAP-38 was evaluated using an ELISA and is shown as a relative value, with the binding response of ICLIST-2 set to 1; the dotted line represents this value. D Structural mapping (blue) of residues that retained at least 20% of their activity compared to ICLIST-2 in the ICLIST-2 alanine scanning experiment. The side chains of these residues are shown in blue as a ball-and-stick model, while ICLIST-2 is shown in orange as a ribbon model and PACAP-38 in grey. The residues enclosed in a box indicate those into which mutations were introduced in ICLIST-11. E The binding of eight variants (ICLIST-4 to ICLIST-11, designed using ProteinMPNN based on ICLIST-2 binding to PACAP-38) is shown as the binding response measured by ELISA. Values are expressed as relative values, with the binding response of ICLIST-2 set to 1, and the dotted line represents the relative binding response of ICLIST-2. All experiments were performed in triplicate, and the results are shown as the mean ± S.D. F Concentration-dependent inhibition of PACAP (1–38)-induced cAMP responses by binders (ICLIST-2, ICLIST-3, and ICLIST-11) measured by the GloSensor cAMP assay. Expi293F cells transiently co-expressing the Glo-22F cAMP biosensor and PAC1R were treated with 1 nM PACAP (1– 38) pre-incubated with serial dilutions of each binder. The data point plotted at log(-12) represents the response to PACAP (1–38) alone (without binder). Data were fitted using a four-parameter sigmoidal curve (Sigmoidal, 4PL, X is concentration). Data are presented as mean ± SEM (n = 3).

Journal: bioRxiv

Article Title: De novo design of mini-proteins as specific binders to PACAP-38, a key mediator of migraine

doi: 10.64898/2026.10.30.763049

Figure Lengend Snippet: A Predicted ΔΔG (kcal/mol) values upon, using FoldX , , and binding response measured by ELISA, for the nine alanine substitutions located in the vicinity of PACAP-38 (left axis). Binding response measured by ELISA (right axis). B Structural mapping (green) of the nine residues located in the vicinity of PACAP-38, which are defined as the core region. The side chains of these nine residues are shown as a ball-and-stick model in green, while ICLIST-2 is shown as an orange ribbon model and PACAP-38 as a grey ribbon model. C Alanine scanning of ICLIST-2. The binding of each mutant to PACAP-38 was evaluated using an ELISA and is shown as a relative value, with the binding response of ICLIST-2 set to 1; the dotted line represents this value. D Structural mapping (blue) of residues that retained at least 20% of their activity compared to ICLIST-2 in the ICLIST-2 alanine scanning experiment. The side chains of these residues are shown in blue as a ball-and-stick model, while ICLIST-2 is shown in orange as a ribbon model and PACAP-38 in grey. The residues enclosed in a box indicate those into which mutations were introduced in ICLIST-11. E The binding of eight variants (ICLIST-4 to ICLIST-11, designed using ProteinMPNN based on ICLIST-2 binding to PACAP-38) is shown as the binding response measured by ELISA. Values are expressed as relative values, with the binding response of ICLIST-2 set to 1, and the dotted line represents the relative binding response of ICLIST-2. All experiments were performed in triplicate, and the results are shown as the mean ± S.D. F Concentration-dependent inhibition of PACAP (1–38)-induced cAMP responses by binders (ICLIST-2, ICLIST-3, and ICLIST-11) measured by the GloSensor cAMP assay. Expi293F cells transiently co-expressing the Glo-22F cAMP biosensor and PAC1R were treated with 1 nM PACAP (1– 38) pre-incubated with serial dilutions of each binder. The data point plotted at log(-12) represents the response to PACAP (1–38) alone (without binder). Data were fitted using a four-parameter sigmoidal curve (Sigmoidal, 4PL, X is concentration). Data are presented as mean ± SEM (n = 3).

Article Snippet: The binding capacity of each binder was analyzed by ELISA, in triple repeats, using biotinylated PACAP-38 (HY-P2609F, MedChemExpress) as the antigen.

Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Mutagenesis, Activity Assay, Concentration Assay, Inhibition, cAMP Assay, Expressing, Incubation

A Selectivity of ICLISTs. HA; Human albumin and BSA; bovine albumin. B Storage stability of ICLIST-2 and ICLIST-11 in mouse plasma, shown as the relative SDS-PAGE band area quantified by ImageJ at 0, 1, 3, 6, and 24 hours relative to a baseline of 1 before storage. C Binding capacity to PACAP-38 before and after 24 hours’ storage in mouse plasma. D,E Binding response to PACAP-38 in 0, 25, 50 and 100% plasma. ICLIST-2 D and ICLIST-11 E are shown respectively. All experiments were performed in triplicate; the mean ± S.D. is shown.

Journal: bioRxiv

Article Title: De novo design of mini-proteins as specific binders to PACAP-38, a key mediator of migraine

doi: 10.64898/2026.10.30.763049

Figure Lengend Snippet: A Selectivity of ICLISTs. HA; Human albumin and BSA; bovine albumin. B Storage stability of ICLIST-2 and ICLIST-11 in mouse plasma, shown as the relative SDS-PAGE band area quantified by ImageJ at 0, 1, 3, 6, and 24 hours relative to a baseline of 1 before storage. C Binding capacity to PACAP-38 before and after 24 hours’ storage in mouse plasma. D,E Binding response to PACAP-38 in 0, 25, 50 and 100% plasma. ICLIST-2 D and ICLIST-11 E are shown respectively. All experiments were performed in triplicate; the mean ± S.D. is shown.

Article Snippet: The binding capacity of each binder was analyzed by ELISA, in triple repeats, using biotinylated PACAP-38 (HY-P2609F, MedChemExpress) as the antigen.

Techniques: Stability, Clinical Proteomics, SDS Page, Binding Assay

a, Representative flow cytometry analysis and quantification of total (surface and intracellular) TRAIL expression in ILC1s and NK cells in the lungs and livers of C57BL/6 mice with or without E0771 cancer cell challenge for 24 h. TRAIL mean fluorescence intensity (MFI) is shown as mean ± s.e.m. b , Representative bioluminescence images and radiance quantification of lung and liver colonization of parental (n = 6) and DR5-deficient ( Tnfrsf10b −/− ; n = 11) E0771 cancer cells. One representative image shown. Data are representative of at least three independent experiments. Radiance quantification is shown as mean ± s.e.m. c , Identification of AP-2α (encoded by Tfap2a ) as a critical regulator of DR5 expression in E0771 cancer cells using a CRISPR-Cas9 screen. Volcano plot showing Log 2 (fold change, FC) versus - Log 2 ( P value) of genes identified by Illumina sequencing analysis. Each point represents an individual gene. Log₂ fold change (Log₂ FC) represents the enrichment or depletion of individual sgRNAs in the DR5-low cell population relative to their abundance in the unsorted library. Positive values denote sgRNAs enriched in DR5-low cells. d , Representative flow cytometry analysis and quantification of DR5 expression in parental and Tfap2a −/− E0771 cancer cells. DR5 MFI is normalized to background signals from Tnfrsf10b −/− E0771 cancer cells. e , Representative bioluminescence images and radiance quantification of lung and liver colonization of parental (n = 6) and AP-2α-deficient ( Tfap2a −/− ; n = 6) E0771 cancer cells. One representative image shown. Data are representative of at least three independent experiments. Radiance quantification is shown as mean ± s.e.m. f , Chromatin immunoprecipitation followed by qPCR (CHIP-qPCR) analysis of AP-2α binding to the Tnfrsf10b gene locus in parental E0771 cancer cells and in cells with knockout of the predicted AP-2α binding sites (BS KO) at the Tnfrsf10b gene locus. Enrichment of DNA immunoprecipitated with anti-AP-2α relative to control IgG was quantified over input DNA. g , Representative flow cytometry analysis and quantification of DR5 expression in parental and BS KO E0771 cancer cells. DR5 MFI is normalized to background signal from Tnfrsf10b −/− E0771 cancer cells. h , Representative bioluminescence images and radiance quantification of lung and liver colonization of parental (n = 5) and BS KO (n = 5) E0771 cancer cells. One representative image shown. Data are representative of at least three independent experiments. Radiance quantification is shown as mean ± s.e.m. i , TNFRSF10B gene copy number in breast cancer patients with or without liver or lung metastases. Violin plots show log 2 -transformed fold changes in copy number, with each dot representing an individual patient sample and the horizontal line indicating the median. j , Association between TNFRSF10B gene copy number and mRNA expression. Expression levels of TNFRSF10B (z-score) are compared between samples with diploid or heterozygous deletion (het loss) of TNFRSF10B . k , Breast cancer patient survival stratified by TNFRSF10B copy number status (diploid versus het loss). P values were calculated using Welch’s t -test ( a , b , d - h ), Wilcoxon rank-sum test ( i , j ), and the log-rank (Mantel-Cox) test ( k ). ns: not significant ( P > 0.05).

Journal: bioRxiv

Article Title: Evasion of Hepatic ILC1 Immunosurveillance Drives Breast Cancer Liver Metastasis

doi: 10.64898/2026.10.26.759951

Figure Lengend Snippet: a, Representative flow cytometry analysis and quantification of total (surface and intracellular) TRAIL expression in ILC1s and NK cells in the lungs and livers of C57BL/6 mice with or without E0771 cancer cell challenge for 24 h. TRAIL mean fluorescence intensity (MFI) is shown as mean ± s.e.m. b , Representative bioluminescence images and radiance quantification of lung and liver colonization of parental (n = 6) and DR5-deficient ( Tnfrsf10b −/− ; n = 11) E0771 cancer cells. One representative image shown. Data are representative of at least three independent experiments. Radiance quantification is shown as mean ± s.e.m. c , Identification of AP-2α (encoded by Tfap2a ) as a critical regulator of DR5 expression in E0771 cancer cells using a CRISPR-Cas9 screen. Volcano plot showing Log 2 (fold change, FC) versus - Log 2 ( P value) of genes identified by Illumina sequencing analysis. Each point represents an individual gene. Log₂ fold change (Log₂ FC) represents the enrichment or depletion of individual sgRNAs in the DR5-low cell population relative to their abundance in the unsorted library. Positive values denote sgRNAs enriched in DR5-low cells. d , Representative flow cytometry analysis and quantification of DR5 expression in parental and Tfap2a −/− E0771 cancer cells. DR5 MFI is normalized to background signals from Tnfrsf10b −/− E0771 cancer cells. e , Representative bioluminescence images and radiance quantification of lung and liver colonization of parental (n = 6) and AP-2α-deficient ( Tfap2a −/− ; n = 6) E0771 cancer cells. One representative image shown. Data are representative of at least three independent experiments. Radiance quantification is shown as mean ± s.e.m. f , Chromatin immunoprecipitation followed by qPCR (CHIP-qPCR) analysis of AP-2α binding to the Tnfrsf10b gene locus in parental E0771 cancer cells and in cells with knockout of the predicted AP-2α binding sites (BS KO) at the Tnfrsf10b gene locus. Enrichment of DNA immunoprecipitated with anti-AP-2α relative to control IgG was quantified over input DNA. g , Representative flow cytometry analysis and quantification of DR5 expression in parental and BS KO E0771 cancer cells. DR5 MFI is normalized to background signal from Tnfrsf10b −/− E0771 cancer cells. h , Representative bioluminescence images and radiance quantification of lung and liver colonization of parental (n = 5) and BS KO (n = 5) E0771 cancer cells. One representative image shown. Data are representative of at least three independent experiments. Radiance quantification is shown as mean ± s.e.m. i , TNFRSF10B gene copy number in breast cancer patients with or without liver or lung metastases. Violin plots show log 2 -transformed fold changes in copy number, with each dot representing an individual patient sample and the horizontal line indicating the median. j , Association between TNFRSF10B gene copy number and mRNA expression. Expression levels of TNFRSF10B (z-score) are compared between samples with diploid or heterozygous deletion (het loss) of TNFRSF10B . k , Breast cancer patient survival stratified by TNFRSF10B copy number status (diploid versus het loss). P values were calculated using Welch’s t -test ( a , b , d - h ), Wilcoxon rank-sum test ( i , j ), and the log-rank (Mantel-Cox) test ( k ). ns: not significant ( P > 0.05).

Article Snippet: After 7 days, 5 × 10 8 cells were stained with biotinylated DR5 antibody (R&D Systems, Cat. #BAF721) for 30 min on ice, washed once with PBS, and then stained with streptavidin-APC (Thermo Fisher Scientific, Cat. #17-4317-82) for 30 min.

Techniques: Flow Cytometry, Analysis, Expressing, Fluorescence, CRISPR, Illumina Sequencing, Chromatin Immunoprecipitation, ChIP-qPCR, Binding Assay, Knock-Out, Immunoprecipitation, Control, Transformation Assay

a , Schematic overview of the CRISPR-Cas9 screening workflow for identifying DR5 regulators in E0771 cancer cells. b , Identification of AP-2α (encoded by Tfap2a ) as a critical regulator of DR5 expression in E0771 cancer cells using a CRISPR-Cas9 screen. Volcano plot showing Log 2 (fold change, FC) versus -Log 2 (False Discovery Rate, FDR) of genes identified by Illumina sequencing analysis. Each point represents an individual gene. c , Top: Position-weight logo of the AP-2α binding motif (from JASPAR; https://jaspar.elixir.no/ ). Bottom: Predicted AP-2α binding sequences (Site 1 and Site 2) located upstream of the murine Tnfrsf10b transcription start site (TSS; position 0). d , e , Diagram ( d ) and sequence ( e ) illustrating the wild-type (WT) Tnfrsf10b gene locus and the generation of AP-2α binding site knockout (BS KO) cells using CRISPR-Cas9 genome editing. Predicted AP-2α binding sites are showing in red ( d , e ); sgRNA sequences in green; and genotyping primers used to identify BS KO cells in blue ( e ). f , (Left) Schematic diagram illustrating the experimental workflow for the in vitro functional assessment of hepatic group 1 innate lymphocytes. ILC1s and NK cells isolated from mouse liver were co-cultured with parental, Tnfrsf10 −/− , or Tfap2a −/− luciferase-expressing E0771 cancer cells. (Right) Cytotoxicity was quantified as the percentage reduction in luciferase-mediated luminescence relative to control target cells cultured in the absence of effectors. The remaining viable target cell population (live cell percentage) is expressed as the mean ± s.e.m. P values were calculated using Ordinary one-way ANOVA test ( f ).

Journal: bioRxiv

Article Title: Evasion of Hepatic ILC1 Immunosurveillance Drives Breast Cancer Liver Metastasis

doi: 10.64898/2026.10.26.759951

Figure Lengend Snippet: a , Schematic overview of the CRISPR-Cas9 screening workflow for identifying DR5 regulators in E0771 cancer cells. b , Identification of AP-2α (encoded by Tfap2a ) as a critical regulator of DR5 expression in E0771 cancer cells using a CRISPR-Cas9 screen. Volcano plot showing Log 2 (fold change, FC) versus -Log 2 (False Discovery Rate, FDR) of genes identified by Illumina sequencing analysis. Each point represents an individual gene. c , Top: Position-weight logo of the AP-2α binding motif (from JASPAR; https://jaspar.elixir.no/ ). Bottom: Predicted AP-2α binding sequences (Site 1 and Site 2) located upstream of the murine Tnfrsf10b transcription start site (TSS; position 0). d , e , Diagram ( d ) and sequence ( e ) illustrating the wild-type (WT) Tnfrsf10b gene locus and the generation of AP-2α binding site knockout (BS KO) cells using CRISPR-Cas9 genome editing. Predicted AP-2α binding sites are showing in red ( d , e ); sgRNA sequences in green; and genotyping primers used to identify BS KO cells in blue ( e ). f , (Left) Schematic diagram illustrating the experimental workflow for the in vitro functional assessment of hepatic group 1 innate lymphocytes. ILC1s and NK cells isolated from mouse liver were co-cultured with parental, Tnfrsf10 −/− , or Tfap2a −/− luciferase-expressing E0771 cancer cells. (Right) Cytotoxicity was quantified as the percentage reduction in luciferase-mediated luminescence relative to control target cells cultured in the absence of effectors. The remaining viable target cell population (live cell percentage) is expressed as the mean ± s.e.m. P values were calculated using Ordinary one-way ANOVA test ( f ).

Article Snippet: After 7 days, 5 × 10 8 cells were stained with biotinylated DR5 antibody (R&D Systems, Cat. #BAF721) for 30 min on ice, washed once with PBS, and then stained with streptavidin-APC (Thermo Fisher Scientific, Cat. #17-4317-82) for 30 min.

Techniques: CRISPR, Screening, Expressing, Illumina Sequencing, Analysis, Binding Assay, Sequencing, Knock-Out, Genotyping, In Vitro, Functional Assay, Isolation, Cell Culture, Luciferase, Control, Flow Cytometry

a , e , Quantification of ILC1s and NK cell numbers in the lungs and livers of C57BL/6 mice fed a control chow diet (CD; n = 9) or high-fat diet (HFD; n = 10) ( a ), or HFD with (n =10) or without (n = 10) Exendin-4 treatment ( e ). Lymphocyte numbers per gram of tissue are shown as mean ± s.e.m. Mice were analyzed without tumor challenge. b , f , Quantification of TCF1 lo GzmC hi ILC1s in the livers of C57BL/6 mice fed with a CD (n = 4) or HFD (n = 5) ( b ), or HFD with (n = 5) or without (n = 5) Exendin-4 treatment ( f ). All mice were analyzed before tumour challenge. Percentages of TCF1 lo GzmC hi cells among ILC1s are shown as mean ± s.e.m. Mice were analyzed without tumor challenge. c , Quantification of cell-surface IL-15 expression in hepatic macrophages (MHCII + TIM4 + ) from CD (n = 5), HFD (n = 5), or HFD with Exendin-4 treatment (n = 5) mice. IL-15 MFI is shown as mean ± s.e.m. Mice were analyzed without tumor challenge. d , Representative bioluminescence images and radiance quantification of lung and liver colonization of E0771 cancer cells in control (n = 5) and Fcgr1 iCre Il15 flox/flox (n = 5) mice. One representative image shown. Radiance quantification is shown as mean ± s.e.m. g , Representative bioluminescence images and radiance quantification of lung and liver colonization of E0771 cancer cells in C57BL/6 mice fed an HFD with (n = 10) or without (n = 5) Exendin-4 treatment following cancer cell challenge. One representative image shown. Radiance quantification is shown as mean ± s.e.m. h , Schematic model illustrating how metastatic breast cancer cells evade hepatic ILC1-mediated immunosurveillance through cancer cell–intrinsic or microenvironmental mechanisms. In healthy liver, abundant ILC1s are activated in response to disseminated cancer cells and provide local innate immune protection. Metastatic breast cancer cells with high DR5 expression are effectively eliminated by ILC1s, whereas cells with reduced DR5 expression (e.g., through TNFRSF10B heterozygous allele loss) evade ILC1-mediated surveillance and survive in the liver. HFD-induced hepatosteatosis reduces IL-15 expression in hepatic macrophages, decreases hepatic ILC1 numbers, and compromises activated TCF1 lo ILC1 populations, driving metastatic outgrowth. GLP-1 receptor agonist (GLP-1 RA) treatment counteracts HFD-induced impairment of liver immunity, restoring ILC1-mediated surveillance and limiting liver metastasis. P values were calculated using Welch’s t -test. ns: not significant ( P > 0.05).

Journal: bioRxiv

Article Title: Evasion of Hepatic ILC1 Immunosurveillance Drives Breast Cancer Liver Metastasis

doi: 10.64898/2026.10.26.759951

Figure Lengend Snippet: a , e , Quantification of ILC1s and NK cell numbers in the lungs and livers of C57BL/6 mice fed a control chow diet (CD; n = 9) or high-fat diet (HFD; n = 10) ( a ), or HFD with (n =10) or without (n = 10) Exendin-4 treatment ( e ). Lymphocyte numbers per gram of tissue are shown as mean ± s.e.m. Mice were analyzed without tumor challenge. b , f , Quantification of TCF1 lo GzmC hi ILC1s in the livers of C57BL/6 mice fed with a CD (n = 4) or HFD (n = 5) ( b ), or HFD with (n = 5) or without (n = 5) Exendin-4 treatment ( f ). All mice were analyzed before tumour challenge. Percentages of TCF1 lo GzmC hi cells among ILC1s are shown as mean ± s.e.m. Mice were analyzed without tumor challenge. c , Quantification of cell-surface IL-15 expression in hepatic macrophages (MHCII + TIM4 + ) from CD (n = 5), HFD (n = 5), or HFD with Exendin-4 treatment (n = 5) mice. IL-15 MFI is shown as mean ± s.e.m. Mice were analyzed without tumor challenge. d , Representative bioluminescence images and radiance quantification of lung and liver colonization of E0771 cancer cells in control (n = 5) and Fcgr1 iCre Il15 flox/flox (n = 5) mice. One representative image shown. Radiance quantification is shown as mean ± s.e.m. g , Representative bioluminescence images and radiance quantification of lung and liver colonization of E0771 cancer cells in C57BL/6 mice fed an HFD with (n = 10) or without (n = 5) Exendin-4 treatment following cancer cell challenge. One representative image shown. Radiance quantification is shown as mean ± s.e.m. h , Schematic model illustrating how metastatic breast cancer cells evade hepatic ILC1-mediated immunosurveillance through cancer cell–intrinsic or microenvironmental mechanisms. In healthy liver, abundant ILC1s are activated in response to disseminated cancer cells and provide local innate immune protection. Metastatic breast cancer cells with high DR5 expression are effectively eliminated by ILC1s, whereas cells with reduced DR5 expression (e.g., through TNFRSF10B heterozygous allele loss) evade ILC1-mediated surveillance and survive in the liver. HFD-induced hepatosteatosis reduces IL-15 expression in hepatic macrophages, decreases hepatic ILC1 numbers, and compromises activated TCF1 lo ILC1 populations, driving metastatic outgrowth. GLP-1 receptor agonist (GLP-1 RA) treatment counteracts HFD-induced impairment of liver immunity, restoring ILC1-mediated surveillance and limiting liver metastasis. P values were calculated using Welch’s t -test. ns: not significant ( P > 0.05).

Article Snippet: After 7 days, 5 × 10 8 cells were stained with biotinylated DR5 antibody (R&D Systems, Cat. #BAF721) for 30 min on ice, washed once with PBS, and then stained with streptavidin-APC (Thermo Fisher Scientific, Cat. #17-4317-82) for 30 min.

Techniques: Control, Tissue, Expressing